Innovative Nanobody-Based Bispecific Therapy Targeting VEGFC and VEGF for Enhanced Cancer Treatment
VHH-P536 is a novel humanized single-domain antibody fusion protein engineered to target both vascular endothelial growth factor C (VEGFC) and vascular endothelial growth factors (VEGF). Currently in the biological testing stage of development, this bispecific construct is optimized for cancer therapy. By engaging both VEGFC and VEGF pathways, VHH-P536 aims to disrupt critical processes in tumor angiogenesis, potentially suppressing cancer progression. The dual-targeted approach leverages advanced protein engineering to offer improved specificity and therapeutic promise, positioning VHH-P536 as a next-generation candidate in anti-cancer drug development.
| Candidate | VHH-P536 |
| Target | vascular endothelial growth factor C (VEGFC) Vascular endothelial growth factors (VEGF) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P536 is available for out-licensing and strategic partnership to accelerate its clinical development. We welcome collaboration inquiries from industry partners interested in advancing innovative oncology therapeutics.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P536 |
Modality
VHH-P536 employs a bispecific antibody fusion modality that integrates an affinity-matured, humanized nanobody targeting VEGFC with the Fc region of a VEGF-Trap construct targeting VEGF, forming a compact therapeutic molecule. This design exploits the inherent advantages of nanobodies—such as small molecular size, enhanced stability, and superior tissue penetration—facilitating effective localization within tumor microenvironments. The dual-targeting architecture enables simultaneous blockade of two key angiogenesis mediators, which is highly relevant for cancer treatment. Expression in human embryonic kidney cells supports optimal folding and function, contributing to its manufacturability and scalability.
Target
VEGFC and VEGF are central molecular targets in tumor biology. VEGFC, a member of the VEGF family, and VEGF itself are critical regulators of angiogenesis and lymphangiogenesis, typically overexpressed in various cancer tissues, particularly within endothelial and tumor-associated stromal cells. Both VEGFC and VEGF drive the formation of new blood vessels, sustaining tumor growth and facilitating metastasis. Targeting VEGFC and VEGF simultaneously disrupts these pathological processes, offering a robust therapeutic strategy. VHH-P536’s precise engagement of VEGFC and VEGF directly addresses key mechanisms underlying cancer progression, making it a strategically valuable asset for oncologic drug development and enabling differentiation from single-target anti-angiogenic therapies.
Mechanism of Action
VHH-P536 acts as a dual angiogenesis inhibitor by binding to both VEGFC and VEGF, thereby intercepting their interaction with their respective receptors on vascular endothelial cells. By doing so, it effectively blocks downstream signal transduction pathways crucial for endothelial cell proliferation, migration, and new blood vessel formation. The blockade of VEGFC and VEGF-driven signaling curtails tumor vascularization, depriving the tumor of essential nutrients and oxygen. Leveraging the versatile nanobody platform, VHH-P536’s framework also allows for modular extension, such as antibody-drug conjugates or additional bispecific constructs, supporting future pipeline development and potential expansion into broader oncology indications.
Cancer
Cancer remains one of the foremost public health burdens globally, encompassing a broad spectrum of malignant diseases with significant morbidity and mortality. Major treatment modalities include surgery, radiation, chemotherapy, and targeted therapies, alongside rapidly evolving immunotherapies. While these approaches have advanced cancer management, limitations such as adverse effects, therapeutic resistance, and incomplete disease control persist, leaving substantial unmet clinical needs. Anti-angiogenic strategies have shown clinical benefit, yet many tumors adapt through alternative pathways, underscoring the need for more comprehensive targeting. VHH-P536, by dual inhibition of VEGFC and VEGF, offers a promising approach to disrupt multiple complementary angiogenesis pathways, potentially overcoming resistance mechanisms and improving clinical outcomes for cancer patients. Its bispecific, nanobody-based design aligns with the search for safer, more effective, and flexible biologic therapies in oncology.